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Objective: To relate systemic biochemical markers of joint metabolism to presence, incidence, and pro-
gression of early-stage radiographic knee and/or hip osteoarthritis (OA).
Method: The cartilage markers uCTX-II, sCOMP, sPIIANP, and sCS846, bone markers uCTX-I, uNTX-I,
sPINP, and sOC, and synovial markers sHA and sPIIINP were assessed by enzyme-linked immunosorbent
assay or radioactive immunoassay in baseline samples of CHECK (Cohort Hip and Cohort Knee), a cohort
study of early-stage symptomatic knee and/or hip OA. Knee and hip radiographs were obtained at
baseline and 5-year follow-up. Presence of OA at baseline was deﬁned as Kellgren and Lawrence
(K&L) ¼ 1 (maximum observed). Incidence of OA was deﬁned as K&L ¼ 0 at baseline and K&L  1 at 5-
year follow-up. Progression of OA was deﬁned as K&L ¼ 1 at baseline and K&L  2 at 5-year follow-up.
Results: Data were available for 801 subjects at baseline and for 723 subjects at both baseline and 5-year
follow-up. Multiple cartilage and synovial markers showed positive associations with presence and
progression of knee and hip OA and with incidence of hip OA, except for negative associations of uCTX-II
and sCOMP with incidence of knee OA. uCTX-II and sCOMP showed multiple interactions with other
biomarkers in their associations with knee and hip OA. Bone markers were positively associated with
presence of radiographic knee OA, but negatively associated with progression of radiographic hip OA.
Conclusion: Especially metabolism in cartilage and synovial matrix appear to be of relevance in knee and
hip OA. The role of bone metabolism appears to differ between knee and hip OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Biochemical markers (biomarkers) of joint metabolism have
been proposed as tools that could help along the challenging roadW.E. Van Spil, Department of
dical Center Utrecht, PO Box
1-88-7557063; Fax: 31-30-
.E. Van Spil), p.m.j.welsing@
asmusmc.nl (S.M.A. Bierma-
Bijlsma), l.roorda@reade.nl
ts), f.lafeber@umcutrecht.nl
ternational. Published by Elsevier Lto efﬁcacious diagnosis and treatment of OA1. Biomarkers are
mostly tested in only small study populations and in isolation
rather than in combination2. Moreover, many studies focus on
subjects with advanced OA2, while it are actually the early-stage
disease subjects that would need to take advantage of any future
biomarkers the most. They are the ones that are most likely to
beneﬁt from disease-modifying drugs and sensitive outcome
measures for clinical trials in such early-stage subjects are eagerly
awaited.
In the current study, ten systemic biomarkers of joint meta-
bolismwere simultaneously assessed in subjects with symptomatic
knee and/or hip OA with no or minimum radiographic OA signs
from CHECK (Cohort Hip and Cohort Knee). Earlier publications on
these biomarkers in CHECK have demonstrated their associationstd. All rights reserved.
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their associations with radiographic knee parameters and pain6.
This time, we investigated to what extent these biomarkers re-
ﬂected concurrent radiographic knee and hip OA and related to
future incidence as well as progression of knee and hip OA during
5-year follow-up. With that, we tried to elucidate aspects of the
pathogenesis of OA.
Method
Cohort characteristics
CHECK is a longitudinal cohort study of 1002 subjects, age
45e65 years at the time of inclusion, with pain and/or stiffness of
one or both knee(s) and/or hip(s)7. They had never or not longer
than 6 months ago consulted a physician for these symptoms for
the ﬁrst time. Subjects with any other pathological condition that
could explain the symptoms (e.g., other rheumatic diseases, pre-
vious joint replacement) were excluded. Subjects needed to be
sufﬁciently ambulatory to attend all follow-up visits.
At baseline, CHECK subjects (79.0% female) were age 56 ± 5
years (mean ± SD) and had a median (25e75% percentiles) BMI of
25.5 (23.3e28.4) kg/m2. Median (25e75% percentiles) WOMAC
scores, ranging between 0 and 100 and higher scores representing
more complaints, were 25 (10e35) for pain, 38 (25e50) for stiff-
ness, and 21 (10e35) for physical function.
Chronic liver disease was reported by three subjects (0.3%) and
chronic renal disease by one subject (0.1%). Excluding these sub-
jects did not change results essentially. Bisphosphonate usewas not
registered systematically. However, since osteoporosis was re-
ported by only four subjects (0.04%), the use of these agents was
presumably low.
Biochemical markers
Biomarker levels were assessed in baseline serum and second
morning void urine samples from CHECK, collected once, in a non-
fasted state, between 8 and 12 AM. Biomarker levels were assessed
by enzyme-linked immunosorbent assay or radioactive immuno-
assay, as was described in more detail previously3. The large-scale
assessment was performed over a number of days. Multiple qual-
ity controls were included and were unremarkable. Intra-plate,
inter-plate, and between-day coefﬁcients of variation (standard
deviation/mean*100%) and median (interquartile range) biomarker
levels were as follows: C-terminal telopeptide of collagen type II
(CTX-II; Urine CartiLaps EIA, Immunodiagnostic systems Ltd., Bol-
don, UK): 10.0%, 9.3%, and 12.4%; 193 (132e281) ng/mmol. Cartilage
oligomeric matrix protein (COMP; AnaMar Med AB, G€oteborg,
Sweden): 5.0%, 4.0%, and 4.2%; 8.5 (7.2e9.9) U/l. N-terminal pro-
peptide of procollagen type IIA (PIIANP; Millipore Corp, Billerica,
MA, US): 15.8%, 7.0%, and 15.7%; 1385 (1087e1771) ng/ml. Chon-
droitin sulphate 846 (CS846; IBEX, Montreal, Canada): 21.5%, 16.9%,
and 15.3%; 70 (54e88) ng/ml. C-terminal telopeptide of collagen
type I (CTX-I, Urine CrossLaps EIA, Immunodiagnostic systems Ltd.,
Boldon, UK): 9.7%, 6.1%, and 2.7%; 152 (100e225) mg/mmol. N-ter-
minal telopeptide of collagen type I (NTX-I, OSTEOMARK NTx Urine,
Wampole Laboratories, Princeton, US): 14.9%, 6.6%, and 10.7%; 37
(28e51) nM BCE/mmol. N-terminal propeptide of procollagen type
I (PINP, UniQ, Orion Diagnostica, Espoo, Finland): 4.4%, 4.5%, and
6.2%; 42 (32e56) ng/ml. Osteocalcin (OC, N-MID Osteocalcin ELISA,
Immunodiagnostic systems Ltd., Boldon, UK): 3.4%, 4.1%, and 4.3%;
13 (10e17) ng/ml. Hyaluronic acid (HA; Corgenix Inc, Westminster,
CO, US): 15.1%, 13.0%, and 17.3%; 27 (17e43) ng/ml. N-terminal
propeptide of procollagen type III (PIIINP; UniQ, Orion Diagnostica,
Espoo, Finland): 5.4%, 3.2%, and 7.2%; 4.1 (3.5e4.9) ng/ml. Urinarybiomarker levels were adjusted for urinary creatinine concentra-
tions (automated kinetic assay, UniCel®DxC 800 Synchron® Clinical
System, Beckman Coulter).
Radiographic data acquisition
Knee and hip radiography were performed at baseline and 5-
year follow-up. Knee radiographs were made in a weight-bearing
posteroanterior view, semiﬂexed. For the hip, weight-bearing
anteroposterior radiographs of the pelvis were made with hips in
15 internal rotation. Radiographs were scored by ﬁve trained ob-
servers according to Kellgren & Lawrence (K&L)8, in a paired
fashion, with known sequence. A random subset of radiographs of
38 subjects was read by all observers, independently of each other,
yielding moderate to substantial inter-observer agreement
(Cohen's kappa ¼ 0.60 for presence of K&L  2 in the knees at 5-
year follow-up).
Deﬁnitions
Knee and/or hip pain were classiﬁed as either present or absent
according to the history of the patient that was obtained by an
experienced rheumatologist.
In each subject one index knee and one index hip were deﬁned
at baseline. When only one of both joints was painful that joint was
considered the index joint. When both or none of the joints were
painful the index joint was randomly selected from both.
Biomarkers were consecutively tested for associations with
presence, incidence, and progression of radiographic OA of the in-
dex joint. Presence of radiographic OA of the index joint at baseline
was deﬁned as K&L ¼ 1 (maximum observed, vs index joints that
scored K&L ¼ 0 at baseline). Incident radiographic OA of the index
joint was deﬁned as a K&L ¼ 0 at baseline and K&L  1 at 5-year
follow-up for the index joint (vs index joints scoring K&L ¼ 0 at
both baseline and 5-year follow-up). Progression of radiographic
OA of the index joint was deﬁned as K&L ¼ 1 at baseline and a K&L
grade 2 in the index joint at 5-year follow-up (vs index joints
showing no increase at 5-year follow-up). These deﬁnitions were
considered most appropriate in these early-stage OA subjects.
Statistical analysis
Cross-sectional associations between biomarkers (independent
variables) and presence of radiographic OA in the index joint
(dependent variable) were investigated by binary logistic regres-
sion, ﬁrst adjusted for concurrent radiographic OA in the contra-
lateral joint (either present or absent) and in hips or knees (either
absent, unilateral, or bilateral) only, and in a next step also adjusted
for age, gender, and BMI.
Associations of baseline biomarkers (independent variables)
with incidence of radiographic OA or progression of radiographic
OA in the index joint during follow-up (dependent variable) were
ﬁrst performedwith adjustment for baseline radiographic OA in the
index joint and its contralateral joint (present or absent) and in hips
or knees (either absent, unilateral, or bilateral) as well as for
radiographic OA changes during follow-up in the contralateral joint
and hips or knees (occurrence of OA incidence or progression: yes
or no). In a next step they were also adjusted for age, gender, and
BMI.
To facilitate comparison between biomarkers and between an-
alyses, biomarkers were logarithmically transformed and stan-
dardized as z-scores. Z-scores reﬂect how many standard
deviations (SD) raw scores deviate from the population mean. As
such, presented odds ratios (OR) indicate the change (ratio) of odds
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pendent of the units of measurement.
Note that not all index joints were painful, since CHECK subjects
could have been included based on pain restricted to either knee(s)
or hip(s). Therefore, interaction between biomarkers and presence
of pain in the index joint could be investigated for all associations
between biomarkers and radiographic OA. Statistically signiﬁcant
interaction between a biomarker and presence of pain indicates
that the association of that biomarker with radiographic OA differs
between painful and non-painful joints. Therefore, whenever
interaction between a biomarker and presence of pain was statis-
tically signiﬁcant, the association of that biomarker with radio-
graphic OA of the index joint was determined for painful and non-
painful index joints separately.
All statistical analyses were performed using SPSS, version 15.0.
Statistical signiﬁcance was deﬁned as P values <0.05, except for
interaction that was considered statistically signiﬁcant at P values
<0.100.Results
Available data
Of the 1002 CHECK subjects, biomarker data were available for
960 subjects. For those subjects, radiographic data were complete
for 801 subjects at baseline and for 723 subjects at both baseline
and 5-year follow-up, see Fig. 1. Subjects undergoing joint
replacement surgery during follow-up were deﬁned as missing
cases at 5-year follow-up, since we were primarily interested inFig. 1. Flow diagram of Kellgren and Lawrence grades of index knees and hips between base
joint and all three other joints at all relevant time points could be included. Subpopulations
the subjects had knee pain only, 17% of the subjects had hip pain only, 42% of the subjects hstructural changes and the decision to undergo surgery is generally
based on many factors that are not related to structural OA signs
only9. At 5-year follow-up, 9 of the in total 1732 knees (0.5%) and 38
of the in total 1738 hips (2.2%) for which K&L grades were available
at baseline had been replaced.
Cross-sectional associations between biomarkers and presence of
OA
Presence of radiographic OA in the index knee appeared to be
positively associated with markers of cartilage and synovial meta-
bolism (uCTX-II OR/SD ¼ 1.304, P ¼ 0.002; sPIIANP OR/SD ¼ 1.339,
P ¼ 0.001; sCS846 OR/SD ¼ 1.253, P ¼ 0.007; sHA OR/SD ¼ 1.248,
P ¼ 0.014; OR/SD, odds ratio per standard deviation). Bone markers
also showed statistically signiﬁcant positive associations, mostly
after adjustment for demographic variables and in painful knees
only (uCTX-I OR/SD ¼ 1.232, P ¼ 0.022; sPINP OR/SD ¼ 1.219,
P¼ 0.040 for painful knees; sOCOR/SD¼ 1.281, P¼ 0.016 for painful
knees) (Table I, top panel).
Presence of radiographic OA in the index hip was associated
with markers of cartilage and synovial metabolism, especially with
sHA (uCTX-II OR/SD ¼ 1.262, P ¼ 0.021; sCOMP OR/SD ¼ 1.280,
P ¼ 0.008; sHA OR/SD ¼ 1.437, P < 0.001) (Table II, top panel).
Associations of baseline biomarkers with incident OA
uCTX-II and sCOMP showed statistically signiﬁcant, but unex-
pectedly negative associations with incidence of radiographic knee
OA in subjects without radiographic OA of the index knee atline and 5-year follow-up. Only subjects with radiographic data available for the index
that were compared in each of the analyses are indicated. In CHECK as a whole, 41% of
ad pain of both knees and hips. K&L, Kellgren and Lawrence grade; rad, radiographic.
Table I
Associations between systemic biomarker levels and presence (top panel), incidence (middle panel), and progression (lower panel) of radiographic knee OA. Adjustment for
covariates was performed stepwise. “Concurrent OA” includes OA in the contralateral joint (either present or absent) and in hips or knees (either absent, unilateral, or bilateral).
“Demographics” includes age, gender, and BMI. Associations are displayed for painful and non-painful index knees separately when interaction between a biomarker and
presence of pain was statistically signiﬁcant. Statistically signiﬁcant values are depicted in bold (P < 0.05, except P < 0.100 for interaction terms in the most right column).
Numbers of subjects per (sub)group are shown in Fig. 1. OR/SD, odds ratio per standard deviation increase; 95% CI, 95% conﬁdence interval; P signiﬁcance
Knee OA presence Adjusted for concurrent OA Adjusted for demographics Interaction with pain
OR/SD 95% CI P OR/SD 95% CI P P
uCTX-II 1.304 1.105e1.538 0.002 1.264 1.058e1.508 0.010 0.765
sCOMP 1.108 0.940e1.305 0.220 0.997 0.838e1.187 0.973 0.093
- No pain 0.834 0.565e1.233 0.363 0.752 0.485e1.167 0.204
- Pain 1.164 0.971e1.397 0.101 1.050 0.866e1.273 0.620
sPIIANP 1.339 1.131e1.584 0.001 1.300 1.093e1.546 0.003 0.219
sCS846 1.253 1.065e1.475 0.007 1.273 1.076e1.506 0.005 0.819
uCTX-I 1.170 0.994e1.378 0.060 1.232 1.030e1.474 0.022 0.535
uNTX-I 1.063 0.904e1.249 0.462 1.080 0.904e1.289 0.395 0.720
sPINP 1.104 0.938e1.298 0.234 1.120 0.944e1.329 0.196 0.024
- No pain 0.713 0.468e1.087 0.116 0.676 0.429e1.063 0.090
- Pain 1.192 0.997e1.425 0.054 1.219 1.009e1.473 0.040
sOC 1.141 0.962e1.352 0.130 1.170 0.975e1.403 0.091 0.033
- No pain 0.733 0.467e1.149 0.176 0.705 0.429e1.157 0.166
- Pain 1.239 1.026e1.498 0.026 1.281 1.046e1.568 0.016
sHA 1.248 1.046e1.490 0.014 1.156 0.951e1.405 0.145 0.209
sPIIINP 1.093 0.924e1.293 0.300 1.009 0.847e1.203 0.916 0.263
Incidence
uCTX-II 0.797 0.631e1.007 0.057 0.765 0.590e0.994 0.045 0.510
sCOMP 0.764 0.596e0.979 0.033 0.725 0.558e0.941 0.016 0.284
sPIIANP 1.004 0.787e1.282 0.972 0.996 0.777e1.276 0.972 0.964
sCS846 1.070 0.831e1.378 0.600 1.055 0.815e1.366 0.686 0.923
uCTX-I 1.150 0.904e1.464 0.255 1.248 0.956e1.629 0.103 0.859
uNTX-I 1.164 0.919e1.476 0.208 1.216 0.938e1.577 0.140 0.889
sPINP 1.136 0.905e1.426 0.272 1.166 0.920e1.478 0.204 0.869
sOC 1.253 0.996e1.576 0.054 1.273 1.000e1.620 0.050 0.533
sHA 1.267 0.971e1.654 0.081 1.309 0.971e1.764 0.077 0.296
sPIIINP 0.815 0.643e1.032 0.089 0.801 0.624e1.028 0.081 0.412
Progression
uCTX-II 1.688 1.262e2.256 <0.001 1.653 1.222e2.235 0.001 0.805
sCOMP 1.481 1.137e1.928 0.004 1.496 1.123e1.992 0.006 0.628
sPIIANP 0.936 0.730e1.199 0.599 0.899 0.692e1.168 0.426 0.165
sCS846 0.938 0.729e1.207 0.618 0.909 0.699e1.181 0.474 0.062
- No pain 0.212 0.036e1.251 0.087 0.145 0.009e2.340 0.174
- Pain 1.078 0.817e1.423 0.594 1.051 0.787e1.402 0.737
uCTX-I 0.986 0.765e1.272 0.916 1.004 0.766e1.317 0.975 0.826
uNTX-I 1.159 0.898e1.496 0.258 1.204 0.911e1.591 0.191 0.441
sPINP 0.954 0.731e1.244 0.729 0.960 0.723e1.274 0.776 0.645
sOC 0.942 0.718e1.234 0.663 0.956 0.712e1.284 0.766 0.554
sHA 1.401 1.072e1.832 0.014 1.303 0.975e1.742 0.073 0.701
sPIIINP 1.248 0.956e1.631 0.104 1.191 0.897e1.581 0.226 0.101
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demographics, OR/SD ¼ 0.765, P ¼ 0.045 after adjustment; sCOMP
OR/SD ¼ 0.764, P ¼ 0.033). sOC, sHA, and sPIIINP showed associa-
tions with incident radiographic knee OA that approached statis-
tical signiﬁcance (sOCOR/SD¼ 1.253, P¼ 0.054; sHAOR/SD¼ 1.267,
P¼ 0.081; sPIIINP OR/SD¼ 0.815, P¼ 0.089) (Table I, middle panel).
Both uCTX-II and sCOMP showed positive associations with
incident radiographic OA in the index hip (uCTX-II OR/SD ¼ 1.404,
P ¼ 0.035; sCOMP OR/SD ¼ 1.396, P ¼ 0.020) and for sPIIANP after
adjustment for demographic variables only (OR/SD ¼ 1.357,
P ¼ 0.035). For uCTX-II interaction with pain in the index hip was
statistically signiﬁcant (P ¼ 0.024). When analysed separately, the
association with incident radiographic OA appeared to hold true
only in subjects with pain in that hip at baseline (OR/SD ¼ 1.889,
P ¼ 0.005), but not in those without (OR/SD ¼ 0.996, P ¼ 0.987)
(Table II, middle panel).
Associations of baseline biomarkers with OA progression
Progression of radiographic knee OA in subjects showing
radiographic OA of the index knee at baseline was again associated
with cartilage and synovial markers (uCTX-II OR/SD ¼ 1.688,P < 0.001; sCOMP OR/SD ¼ 1.481, P ¼ 0.004; sHA OR/SD ¼ 1.401,
P ¼ 0.014). sCS846 showed statistically signiﬁcant interaction with
presence of pain of the index knee at baseline. When analysed in
subjects with and without pain separately, sCS846 approached a
statistically signiﬁcantly negative association with progression of
radiographic knee OA in subjects without pain, but not in those
with pain (OR/SD ¼ 0.212, P ¼ 0.087 in subjects without knee pain,
OR/SD¼ 1.078, P ¼ 0.594 in subjects with knee pain) (Table I, lower
panel).
Progression of radiographic OA of the index hip appeared to be
positively associated with sCS846 in subjects with pain of the index
hip at baseline (OR/SD ¼ 1.949, P ¼ 0.031). Progression of hip OA
was negatively associated with both uCTX-I and sOC (uCTX-I OR/
SD¼ 0.572, P¼ 0.014; sOC OR/SD¼ 0.623, P¼ 0.027) and tended to
be negatively associated with sPINP (OR/SD ¼ 0.628, P ¼ 0.050)
(Table II, lower panel).
Interaction between biomarkers
Since uCTX-II and sCOMP showed the most consistent associa-
tions with radiographic knee and hip OA, they were tested for
interaction with the other biomarkers in their associations with
Table II
Associations between systemic biomarker levels and presence (top panel), incidence (middle panel), and progression (lower panel) of radiographic hip OA. Adjustment for
covariateswas performed stepwise. “Concurrent OA” includes OA in the contralateral joint (either present or absent) and in hips or knees (either absent, unilateral, or bilateral).
“Demographics” includes age, gender, and BMI. Associations are displayed for painful and non-painful index hips separately when interaction between a biomarker and
presence of pain was statistically signiﬁcant. Statistically signiﬁcant values are depicted in bold (P < 0.05, except P < 0.100 for interaction terms in the most right column).
Numbers of subjects per (sub)group are shown in Fig. 1. OR/SD, odds ratio per standard deviation increase; 95% CI, 95% conﬁdence interval; P signiﬁcance
Hip OA presence Adjusted for concurrent OA Adjusted for demographics Interaction with pain
OR/SD 95% CI P OR/SD 95% CI P P
uCTX-II 1.262 1.036e1.538 0.021 1.210 0.978e1.498 0.079 0.415
sCOMP 1.280 1.066e1.537 0.008 1.253 1.030e1.524 0.024 0.459
sPIIANP 0.956 0.799e1.144 0.626 0.953 0.793e1.147 0.613 0.998
sCS846 1.028 0.857e1.233 0.769 1.028 0.855e1.237 0.766 0.421
uCTX-I 1.002 0.838e1.198 0.985 0.986 0.809e1.201 0.886 0.780
uNTX-I 1.078 0.902e1.288 0.411 1.080 0.886e1.315 0.446 0.503
sPINP 0.922 0.770e1.105 0.379 0.899 0.742e1.089 0.277 0.290
sOC 0.859 0.711e1.036 0.112 0.802 0.653e0.984 0.034 0.874
sHA 1.437 1.172e1.760 <0.001 1.252 1.006e1.559 0.044 0.997
sPIIINP 1.036 0.860e1.247 0.711 1.030 0.845e1.255 0.770 0.120
Incidence
uCTX-II 1.404 1.024e1.925 0.035 1.465 1.035e2.072 0.031 0.024
- No pain 0.996 0.612e1.620 0.987 1.077 0.624e1.857 0.790
- Pain 1.889 1.213e2.941 0.005 1.872 1.156e3.032 0.011
sCOMP 1.396 1.055e1.848 0.020 1.423 1.059e1.911 0.019 0.299
sPIIANP 1.280 0.968e1.692 0.083 1.357 1.022e1.804 0.035 0.865
sCS846 0.965 0.725e1.285 0.808 0.989 0.740e1.321 0.938 0.868
uCTX-I 1.108 0.855e1.437 0.437 1.083 0.819e1.432 0.578 0.451
uNTX-I 1.039 0.798e1.351 0.778 1.029 0.770e1.375 0.848 0.786
sPINP 1.133 0.865e1.483 0.364 1.064 0.802e1.410 0.667 0.556
sOC 0.976 0.748e1.272 0.856 0.859 0.643e1.148 0.305 0.303
sHA 0.943 0.728e1.220 0.654 0.839 0.628e1.122 0.237 0.940
sPIIINP 1.033 0.768e1.390 0.830 1.060 0.785e1.431 0.703 0.230
Progression
uCTX-II 0.769 0.480e1.232 0.274 0.866 0.523e1.433 0.576 0.039
- No pain 0.467 0.161e1.353 0.161 0.508 0.158e1.627 0.254
- Pain 0.858 0.488e1.512 0.597 0.917 0.510e1.651 0.773
sCOMP 1.118 0.717e1.745 0.623 1.150 0.709e1.864 0.572 0.731
sPIIANP 0.851 0.557e1.300 0.455 0.777 0.491e1.230 0.281 0.179
sCS846 1.391 0.858e2.256 0.180 1.373 0.848e2.224 0.197 0.069
- No pain 0.679 0.266e1.736 0.419 0.620 0.221e1.746 0.366
- Pain 1.949 1.064e3.571 0.031 1.977 1.068e3.661 0.030
uCTX-I 0.572 0.366e0.894 0.014 0.537 0.326e0.884 0.015 0.225
uNTX-I 0.734 0.479e1.123 0.154 0.726 0.454e1.159 0.179 0.568
sPINP 0.628 0.394e0.999 0.050 0.627 0.382e1.030 0.065 0.150
sOC 0.623 0.409e0.948 0.027 0.558 0.350e0.888 0.014 0.360
sHA 0.922 0.622e1.368 0.687 0.925 0.586e1.462 0.739 0.398
sPIIINP 0.631 0.390e1.019 0.059 0.700 0.416e1.179 0.181 0.600
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the pathogenetic mechanisms behind uCTX-II and sCOMP release.
Statistically signiﬁcant interaction between biomarkers indicates
that the association of the one biomarker on the outcome is (partly)
dependent on the other biomarker. Therefore, when interaction of
uCTX-II or sCOMP with another biomarker was statistically signif-
icant (P < 0.100, data not shown) the association of uCTX-II or
sCOMP with radiographic OA was tested at different levels of that
other biomarker, as is shown in Fig. 2.
For the knee, especially at high sHA levels (tertiles) uCTX-II
appeared to be positively associated with presence of radio-
graphic OA. The negative association between uCTX-II and radio-
graphic knee OA incidence that was observed in the population as a
whole (OR/SD ¼ 0.765, P ¼ 0.045, Table I) generally appeared to
hold true for lower levels of uCTX-I, uNTX-I, and sOC (Fig. 2(A),
middle column) but not for higher levels. Finally, uCTX-II appeared
to show positive associations with progression at lower sPIIANP
levels, but not at higher sPIIANP levels. COMP did not show inter-
action with other biomarkers in its associations with radiographic
knee OA (Fig. 2(A)).
For the hip, sCOMP showed statistically signiﬁcant interaction
with sCS846 in its associationwith presence of radiographic hip OA.
It appeared that the positive association between sCOMP andpresence of radiographic hip OA gradually increased with
increasing sCS846 levels (Fig. 2(B), left column). uCTX-II appeared
to be positively associated with radiographic OA incidence at low
sOC levels, but not at higher sOC levels. Likewise, uCTX-II was
positively associated with radiographic hip OA incidence at lower
sHA and sPIIINP levels, but not at higher levels (Fig. 2(B), middle
column).
Discussion
The current study illustrates how systemic biochemical marker
levels relate to presence, incidence, and progression of early-stage
radiographic knee and hip OA. Among the investigated markers,
CTX-II and COMP appeared superior in their associations with
radiographic knee and hip OA. Moreover, the observation that CTX-
II was associated with progression of radiographic OA of the index
knee at lower PIIANP levels only, conﬁrmed earlier ﬁndings that
dissociation between synthesis and degradation of collagen type II
is relevant for radiographic knee OA progression10e13. We did,
however, not ﬁnd this for presence and incidence of radiographic
knee OA and not at all for radiographic hip OA.
An unexpected ﬁnding on CTX-II and COMP, however, was that
their levels were negatively associated with incidence of
Fig. 2. Bar graphs showing associations of uCTX-II or sCOMP with presence, incidence, and progression of radiographic knee and hip OA at different levels of a second biomarker
whenever justiﬁed based on statistically signiﬁcant interaction. The number of subjects per tertile is indicated on the x-axis. Error bars represent 95% conﬁdence intervals. Odds
ratio ¼ 1 is indicated by horizontal dotted lines in each of the graphs. Statistically signiﬁcant differences between OR are indicated by an asterisk. OR/SD, odds ratio per standard
deviation increase; P, signiﬁcance.
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W.E. Van Spil et al. / Osteoarthritis and Cartilage 23 (2015) 1388e13971394radiographic knee OA. For CTX-II this negative association was
especially found at lower levels of bone degradation and synthesis
markers. This may indicate that a less dynamic (persistently low)
cartilage and (subchondral) bone turnover (matrix turnover and
with that adaptation and repair) are disadvantageous in the early
phases of knee OA. However, the negative associations with inci-
dent knee OAwere exactly opposite to the positive associations that
were found in other analyses.
Previous data from CHECK suggest that CTX-II is intimately
associated with bone metabolism, as opposed to other cartilage
markers3,4. The current study again supports the hypothesis that
CTX-II does not only relate to cartilage but also to bone metabolism,
as CTX-II showed interaction with markers of both cartilage and
bone metabolism. None of the other cartilage markers showed
interaction with markers of bone metabolism.
The observation that serum PIIANP levels were increased in
presence of radiographic knee OA and tended to be increased in
subjects showing incident radiographic hip OA during follow-up
adds to contradictory literature data showing both positive and
negative associations between serum PIIANP levels and progres-
sion of radiographic knee OA10,14. This inconsistency between
studies may result from the fact that the extent of collagen syn-
thesis in osteoarthritic cartilage differs between histological-
histochemical OA grades, ﬁrst increasing between lower grades
and then decreasing between higher grades15. The positive asso-
ciations in our study may therefore be considered in line with the
early-stage OA in this cohort, although cartilage damage has been
shown to be already substantial in joints scoring K&L ¼ 112.
We found serum CS846 levels to be positively associated with
presence of radiographic knee OA, whichwould indicate that CS846
release is related to unbeneﬁcial processes within the pathogenesis
of OA. This was further substantiated by the observation that COMP
levels were especially associated with presence of radiographic hip
OA at higher CS846 levels. CS846 might represent the increased
glycosaminoglycan turnover that eventually causes collagenol-
ysis16,17. CS846 levels in synovial ﬂuid were increased in various
knee pathologies including primary OA18 and experimental OA19,
were higher in late-stage as compared to early-stage OA, and were
positively associated with COMP levels18. Most of the few human
studies on CS846 levels in serum did not at all ﬁnd associations
with radiographic knee OA severity or progression20e22, although
one other study contradictedwith ours in thatmean CS846 levels in
serial plasma samples appeared to be negatively associated with
concurrent joint space narrowing of the knee23.
The positive associations that were found between synovial
markers and radiographic knee OA once more underscore the po-
tential relevance of synovitis in early-stage knee OA24e28. Less is
known about (markers of) synovitis in hip OA2. Serum HA and
PIIINP levels were not associated with symptom severity, joint
space width, and subchondral bone sclerosis of the hip in 376 hip
OA patients of the ECHODIAH cohort when analysed cross-
sectionally29. Serum HA levels were, however, shown to be asso-
ciated with 3-year hip OA progression when deﬁned as joint space
narrowing 0.5 mm or requirement for total hip arthroplasty, but
serum PIIINP levels were not30. In our study, serum HA levels were
positively associated with presence of radiographic hip OA, but not
with its incidence or progression. Neither did we ﬁnd statistically
signiﬁcant associations between PIIINP levels and radiographic hip
OA. However, PIIINP levels unexpectedly tended to be negatively
associated with progression of radiographic hip OA and CTX-II
levels were positively associated with radiographic hip OA inci-
dence at lower PIIINP levels only. These ﬁndings were unexpected,
since it is unlikely that any intra-articular process that is charac-
terized by ﬁbrosis would be associated with a favourable outcome
in hip OA, andmight have resulted frommultiple testing or from itslimited tissue speciﬁcity31,32. Likewise, the positive interaction
between HA and CTX-II levels in the association with presence of
radiographic knee OA seems more appropriate than the negative
interaction between both in the association with radiographic hip
OA incidence, also based on previous ﬁndings in other studies on
OA30,33 and RA13,34.
Markers of bone metabolism showed apparently inconsistent
associations with radiographic knee and hip OA. We did ﬁnd pos-
itive associations of both bone degradation (CTX-I) and synthesis
markers (PINP and OC) with presence of early-stage radiographic
knee OA. This may indicate that a high bone turnover state is an
aggravating factor in the early stages of radiographic knee OA. The
bone markers may be related to the subchondral bone changes that
happen in OA and, as such, our ﬁndings would be in line with the
rationale for testing calcitonin35, bisphosphonates36, and risedro-
nate37 and strontium ranelate38 in knee OA. Our ﬁndings are in
accordance with the increased urinary CTX-I and NTX-I levels in
progressive knee OA patients as compared to non-progressive knee
OA patients and/or healthy controls39 and the increased serum OC
levels that were found in generalized OA patients40. However, they
are in contradiction with other studies actually showing decreased
bone marker levels in knee OA patients33,41.
As opposed to our ﬁndings on knee OA, we found negative as-
sociations of bone marker levels with presence and progression of
radiographic hip OA. Moreover, CTX-II appeared to be positively
associated with radiographic hip OA incidence at lower OC levels
only. These ﬁndings might indicate that high levels of bone turn-
over and decreased bone mass and/or mineral density would pro-
tect against hip OA and would argue for the hypothesis that
osteoporosis and OA are inversely related40. Literature data on bone
markers in hip OA are somewhat contradictory. Some studies did
not ﬁnd associations between systemic bone marker levels and
concurrent or future hip OA29,42, one found urinary CTX-I levels to
be decreased in hip OA patients as compared to healthy controls but
to be positively associated with radiographic progression and no
association with hip OA progression for serum PINP levels30, and
one found increased serum ICTP (cross-linking C-terminal telo-
peptide of collagen type I) levels to be associated with rapidly
destructive hip OA but none of the other bone markers43,44.
The fact that associations with bone markers were different for
knee and hip OA in our study can be due to pathogenetic differ-
ences between these joints45. It has been previously shown that the
relationship between bonemineral density can differ between joint
sites5. It can also be that our contradictory ﬁndings stem from the
fact that K&L grades represent different OA stages between knee
and hip45,46 and that the inﬂuence of bone mineral density differs
between OA stages47. Finally, it can be that the causeeeffect relation
is different between the associations that were found for both
joints. Bone mineral density changes and according bone marker
changes may have caused but may also have been the consequence
of the OA process. Altered joint loading due to hip and/or knee OA
symptoms has been shown to inﬂuence bonemineral density in the
lower extremities48,49.
In the current study on early-stage OA, radiographic OA needed
to be deﬁned as K&L ¼ 1. However, joints that were scored K&L ¼ 0
in these symptomatic subjects may have had structural OA changes
not yet evident on radiographs12 and K&L ¼ 1 is considered only
doubtful OA45. However, in the current study, presence of K&L ¼ 1
changes in itself was statistically signiﬁcantly associated with
future K&L grade increasewhen all subjects were analysed together
(OR ¼ 1.884, 95% CI ¼ 1.413e2.511, P < 0.001 for the knee;
OR¼ 1.586, 95% CI ¼ 1.037e2.427, P ¼ 0.033 for the hip). Therefore,
we think that these subcategories represented different pop-
ulations in the current study and that separate analysis was justi-
ﬁed. Notwithstanding, contrasts between subjects that were
W.E. Van Spil et al. / Osteoarthritis and Cartilage 23 (2015) 1388e1397 1395deﬁned as being with and without radiographic OA in the current
study may not always have been maximum and differences of
biomarker levels between them may be underestimated.
Strengths of the current study are its large size, its 5-year follow-
up, and the large number of biomarkers that were simultaneously
assessed. This study has limitations also. First, serial biochemical
marker assessments would have been preferable over the current
cross-sectional assessment. However, due to the large number of
biomarkers this was infeasible at the moment, but may be recon-
sidered in the future. Second, coefﬁcients of variationwere>10% for
some of the biomarker assessments, which may have caused that
we missed some associations between biomarker levels and
radiographic OA parameters. Third, radiographs at shorter intervals
might have been informative, since OA progression may be phasic
instead of linear50. The current design does not ascertain that
subjects that showed OA progression at 5-year follow-up did
actually have active disease at baseline. Fourth, comparison of
biomarker levels between healthy and OA subjects would have
been interesting, but healthy control subjects without any joint
complaints were not included in the current study. Fifth, plain
radiography has its limitations with regard to visualizing cartilage
damage and does not visualize synovial tissue changes. Moreover,
confounding by concurrent metabolism in other joints than knee
and hip cannot be ruled out. Finally, using the K&L classiﬁcation
system did not allow investigation of associations between bio-
markers and speciﬁc radiographic OA features. Fourth, direct
measures of bone density (e.g., dual-energy X-ray absorptiometry,
DEXA) would have supported our tentative conclusions on the as-
sociations between bone metabolism and OA. Such data were not
available however.
In conclusion, especially biomarkers of cartilage and synovial
metabolism were found to be associated with radiographic knee
and/or hip OA in this cohort of symptomatic subjects with only
early-stage radiographic OA. As such, higher levels of cartilage and
synovial matrix turnover apparently are important characteristics
of knee and hip OA in their early stages already. This does not
exclude involvement of subchondral bone turnover in OA, since
markers of bonemetabolismmay reﬂect systemic bonemetabolism
as a whole rather than subchondral bone metabolism only. Bone
markers showed associations that differed between knee and hip,
which might indicate a different role of bone metabolism between
knee and hip OA.
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